PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
• 英文别名: 2-[[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-octadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C48H85NO8P+
• 分子量: 835.2
• InChiKey: FAUYAENFVCNTAL-PFFNLMTBSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  13.7
• 重原子数：
  58
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• DISRUPTION OF THE INTERACTION BETWEEN AMYLOID BETA PEPTIDE AND DIETARY LIPIDS
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20170354669A1

  公开（公告）日：2017-12-14

  The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associated cognitive disorders, multiple system atrophy, and rare neuroaxonal dystrophies, such as Niemann-Pick type C disease (NPC) and Gaucher's disease comprising administering an inhibitor to disrupt the interaction between Aβ or αS and neuronal lipids. The invention further relates to assays for identifying agents that reduce interaction between Aβ or αS and neuronal lipids. Lastly, the invention relates to methods and compositions for intranasal administration of fatty acids or lipids containing fatty acid acyl chains of dietary lipids for promoting central nervous system health and/or prevention or treatment of neurodegenerative disorders.
• [EN] PHOSPHOLIPID COMPOSITIONS<br/>[FR] COMPOSITIONS DE PHOSOPHOLIPIDES
  申请人：MACHAVERT PHARMACEUTICALS LLC

  公开号：WO2018005735A9

  公开（公告）日：2018-02-01

  [EN] Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.
  [FR] L'invention concerne des compositions comprenant un extrait de jaune d'oeuf modifié destiné à être utilisé en tant qu'agent anticancéreux efficace. L'extrait de jaune d'oeuf modifié comprend des fractions spécifiques de phosphatidylcholines et de sphingomyélines modifiées et produites à partir d'une synthèse chimique appliquée à l'extrait qui produisent un effet bénéfique sur l'inhibition de la croissance des cellules cancéreuses. L'invention concerne également des méthodes d'administration de ces compositions.